127 filings
8-K
FEMY
Femasys Inc
24 Apr 24
Regulation FD Disclosure
9:11am
S-8
FEMY
Femasys Inc
5 Apr 24
Registration of securities for employees
5:17pm
S-8
FEMY
Femasys Inc
5 Apr 24
Registration of securities for employees
5:07pm
10-K
2023 FY
FEMY
Femasys Inc
Annual report
28 Mar 24
5:05pm
8-K
FEMY
Femasys Inc
28 Mar 24
Results of Operations and Financial Condition
4:23pm
8-K
216e4p i7e
20 Mar 24
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
8:18am
8-K
axg7p
6 Mar 24
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
9:09am
8-K
pn6dba5x565jpz
28 Feb 24
Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation 1
9:16am
8-K
zq2dvyp e8w4
6 Feb 24
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
8:47am
EFFECT
wnyahyljhm3byr7
11 Dec 23
Notice of effectiveness
12:15am
424B3
durqcruf97ji
8 Dec 23
Prospectus supplement
9:28am
CORRESP
0jszb1iwra b2cm0y
6 Dec 23
Correspondence with SEC
12:00am
UPLOAD
yraqqshz9de
5 Dec 23
Letter from SEC
12:00am
8-K
1l6wity5fwgxf8h3w
29 Nov 23
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
4:05pm
D
jvows97lwqpnj2at6y8
22 Nov 23
$6.85 mm in debt / options / securities to be acquired, sold $6.85 mm, 4 investors
4:12pm
8-K
zcakk mt86
21 Nov 23
Departure of Directors or Certain Officers
5:30pm
8-K
dzae6
15 Nov 23
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
5:19pm
8-K
wwkfdzl
14 Nov 23
Femasys Inc. Announces Financial Results for the Third Quarter Ended
12:00am